Work

Investigating the Transcriptional Regulatory Mechanisms Driving SOX2 Overexpression in Cancer

Year: 2023
Type: dissertation
Abstract: SRY-box transcription factor 2 (SOX2) is a crucial transcription factor that regulates differentiation and self-renewal in embryonic and progenitor cells. SOX2 overexpression also contributes to tumourigenesis in more than 25 different cancer types, including breast and lung cancer, where it is linked to poor patient outcomes. Although SOX2 plays a key role in regulating gene expression throughout development, the molecular mechanisms that control its own expression remain mostly unknown. In this thesis, I aimed to understand the regulatory network that drives SOX2 expression in epithelial cells and describe the molecular players involved in its misregulation during disease. I identified two genomic regions, SRR124 and SRR134, with increased enhancer features in breast and lung carcinoma. Reporter assays demonstrated that both SRR124 and SRR134 act as enhancers, whereas deletion of the SRR124–134 cluster downregulated SOX2 expression in breast and lung cancer cells. SOX2 downregulation reduced chromatin accessibility and disrupted expression of multiple genes associated with epithelium development. Cross-species analysis showed that both SRR124 and SRR134 are highly conserved across mammals and that these regions display enhancer features during development of the digestive and respiratory systems in both human and mouse. Cancer patient ATAC-seq revealed that SRR124 and SRR134 are accessible in multiple types of cancer and that accessible chromatin at these regions is significantly associated with SOX2 overexpression in breast and lung cancer. Investigation of upstream regulators showed that expression of the pioneer factor FOXA1 increases, whereas NFIB decreases SRR124–134 enhancer activity. In breast cancer cells, I found that estrogen is a SOX2 repressor that inhibits SRR134 activity. Continuous estrogen exposure leads to changes in chromatin accessibility associated with NFIB, followed by transcriptome reprogramming correlated with a more differentiated luminal phenotype. In this state, breast cancer cells maintain a highly repressed SOX2 gene through a transcriptionally repressed SRR124–134 cluster that is kept in a poised state due to potential co-occupancy of ER, FOXA1, and NFIB. Based on these findings, I propose that the SRR124–134 cluster normally controls SOX2 expression during the development of multiple epithelial tissues; aberrant accessibility of this cluster then drives SOX2 overexpression in breast and lung cancer cells.
Language: English
Open Access status: green
OpenAlex ID: W7133001365
Cites: 440
Cited by:
Related to: 10